Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsEventsSponsored PodcastsSponsored VideosWebcastsWhitepaperseBooks
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Bjorn Reynolds

Advertisement

Founder and CEO, Safeguard Global

Articles by Bjorn Reynolds

Taking Advantage of ‘Hidden Gem’ Talent Hubs

ByBjorn Reynolds
January 30th 2026

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

Advertisement

Latest Updated Articles

  • Taking Advantage of ‘Hidden Gem’ Talent Hubs
    Taking Advantage of ‘Hidden Gem’ Talent Hubs

    January 30th 2026



Advertisement
Advertisement

Trending on PharmExec

1

FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease

2

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

3

Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

4

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

5

Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us